Wegweisend. - SöDAK 2009

4.3 NuKlEOTIDE RT-INHIBITOREN / NuClEAR RT-INhIBITORS
• Gutes Ansprechen einer Kombinationstherapie von Trizivir/Tenofovir bei Vorbehandelten über 96 Wochen. CTP-
Score vs.1.2 als prädiktives Tool für den Therapieerfolg.
stephan Dupke, Bettina hintsche, Christoph mayr, frank schlote, arend moll, felise krauthausen, Daniel Prziwara,
Dorothea schleehauf, siegfried köppe, andreas Carganico, axel Baumgarten, markus müller, thomas Berg, martin
obermeier; Berlin, stutgart
4.4 PROTEASEHEmmER (PI) / PROTEASE INhIBITORS (PI)
POSTER WALKS
PW1, PW2, PW3: Donnerstag, 25. Juni 15.00 - 16.00 uhr
PW4, PW5, PW6: freitag, 26. Juni 15.00 - 16.00 uhr
Die Posterausstellung befindet sich in der halle 9.1.2.
PW2 • 48-wk Safety and Efficacy of Darunavir/ritonavir (DRV/r) in Treatment-experienced Children and Adolescents in
DELPHI
s. spinosa-guzman, P. Vis, V. sekar, B. Van Baelen; mechelen
• Efficient Suppression of Minority Quasispecies of Drug-Resistant Viruses Present at Primary HIV-1 Infection by
Boosted Protease Inhibitor Containing ART
karin J. metzner, Pia rauch, Viktor von wyl, herbert kuster, Jürg Böni, rainer weber, huldrych f. günthard; Zürich,
erlangen
• Efficacy and Safety of 48 Weeks Maintenance with Once-Daily ATV vs ATV/r in Suppressed Patients after
Induction with ATV/r
iris scheirich, J.-f. Delfraissy, s. moreno, J. sanz-moreno, g. Carosi, V. Pokrovsky, a. lazzarin, g. Pialoux, a. Balogh,
e. Vandeloise, u meyer-Bunsen, g. leleu; Paris, madrid, Brescia, moscow, milan, Braine l‘alleud, münchen
• Low nadir CD4 count predicts failure of LPV/r monotherapy (MOST) due to unexpectedly high failure rate in
monotherapy arm
Christine gutmann, milos opravil, Christoph fux, hansjakob furrer, laurent-arthur Decosterd, matthias Cavassini,
sabine Yerly, Bernard hirschel, Pietro Vernazza, and the swiss hiV Cohort study; st. gallen, Zürich, Bern, lausanne,
geneva
• Cost Effectiveness Analysis of Atazanavir versus Lopinavir in the Treatment of Naïve HIV Patients in Germany
iris scheirich, Per-olof thuresson, aljoscha s. neubauer, Bart heeg; rotterdam, münchen
• Vergleich der Kosten-Nutzen-Relation verschiedener Proteaseinhibitoren bei der Erstlinien-Therapie von HIV-
Patienten unter Anwendung der vom IQWIG vorgeschlagenen Methode der Effizienzgrenze
Verena Donatz, erik smets, andrew hill, matthias stoll; neuss, mechelen, hannover, liverpool
• Efficacy and Safety by Baseline HIV-RNA and CD4-Count in Treatment-Naive Patients Treated With Atazanavir/r
and Lopinavir/r in the CASTLE Study
iris scheirich, J. uy, r. Yang, a. thiry, J. absalon, a. farajallah, J. maa, e. grützner, D. mcgrath; wallingford,
münchen
Session F • Susceptibility of Diverse HIV-1 Patient Isolates to the Maturation Inhibitor, Bevirimat, is Determined by Clade-
Specific Polymorphisms in Gag CA-SP1
thomas klimkait, karl salzwedel, severine louvel, m. sakalian, m. reddick, C. finnegan, D. martin, s. mc Callister,
francois hamy, g. allaway; Basel, gaithersburg
• Once-daily Darunavir used in routine clinical care produces trough Darunavir-drug-concentrations in excess of
30x the protein-corrected (PC)EC50 for wild-type HIV
Claire robertson, a. n. Jayasuriya, C. smith, n. Dufty, a. Berry, C. stradling, steve taylor; Birmingham, london
• Safety of Darunavir/ritonavir 800/100 mg Once-daily vs Lopinavir/ritonavir in Treatment-naïve, HIV-1-infected
hepatitis-B- and/or C-coinfected patients in the ARTEMIS trial.
Bernd gmeinhart, Christiane möcklinghoff, armin rieger, Veronique touzeau-römer, eric lefebvre, inge Dierynck,
Vanitha sekar, Carline Vanden abeele, ludo lavreys, esther gehmacher; wien, mechelen, Yardley
Session A • Lopinavir/Ritonavir plus Atazanavir in Comparison to Lopinavir/Ritonavir plus Nucleoside Analogues (Zidovudin
plus Lamivudin) - The LORAN-Trial, A Phase III-Study
kai ulbricht, matthias stoll, georg m. Behrens, Bernd salzberger, heiko Jessen, arne Jessen, Birger kuhlmann, hans
heiken, andreas trein, reinhold ernst schmidt; hannover, regensburg, Berlin, stuttgart
• Long term outcome of 8 infants, which started treatment with 2 NRTI + Nelfinavir in the first year of life
Bernd Buchholz, steffen hien, matthias Beichert, matthias Dürken, horst schroten; mannheim
Abstract
P417
Abstract
P418
P419
P420
P421
P422
P423
P424
P425
P426
P427
P428
P429
41